Key takeaways
- The 2026 and 2027 Lists name BPC-157 in S0, the class for substances with “no current approval by any governmental regulatory health authority for human therapeutic use”.
- BPC-157 was the first substance WADA named by way of example in S0, in the 2022 List, after what WADA called “a recent re-evaluation of its status”.
- Under the World Anti-Doping Code, presence in a sample, use and possession are each violations; for a Specified Substance the default ban is two years, or four if the violation is shown to be intentional.
- Three US cases since 2023 began without a positive test: a self-report, a declaration and a whistleblower tip that led to an investigation.
- WADA’s 2027 List, in force from 1 January 2027, adds “peptides” to the S0 examples, and its notes warn that an unnamed peptide “may still be prohibited”.
01What does the WADA Prohibited List say about BPC-157?
The Prohibited List is a mandatory International Standard under the World Anti-Doping Code, revised every year. BPC-157 sits in its first class, S0.
The 2026 List, in force since 1 January 2026, defines S0 as “any pharmacological substance which is not addressed by any of the subsequent sections of the List and with no current approval by any governmental regulatory health authority for human therapeutic use”, giving as examples drugs in development or discontinued, designer drugs and veterinary-only substances. It goes on: “This class covers many different substances including but not limited to BPC-157”, followed by 2,4-dinitrophenol (DNP), ryanodine receptor-1-calstabin complex stabilizers and troponin activators.
The class header reads: “All prohibited substances in this class are Specified Substances.” That label affects the length of a sanction; it does not take a substance off the List. The List’s introduction, quoting the Code, says Specified Substances “should not in any way be considered less important or less dangerous than other doping substances or methods.”
| List | In force | BPC-157 | S0 wording |
|---|---|---|---|
| 2022 | 1 Jan 2022 | Named in S0, the first substance WADA named there by way of example. | Examples: drugs in development or discontinued, designer drugs, veterinary-only substances. |
| 2026 | 1 Jan 2026 | Named in S0, alongside DNP, ryanodine receptor-1-calstabin complex stabilizers and troponin activators. | Same examples. All S0 substances are Specified. |
| 2027 | 1 Jan 2027 | Named in S0, with the same companions. | Adds “peptides” to the examples. All S0 substances are Specified. |
02What does “prohibited at all times” mean under the Code?
The List defines it as prohibited in and out of competition. The World Anti-Doping Code sets what counts as a violation and what follows. These are the 2021 Code’s articles.
It is each athlete’s “personal duty to ensure that no Prohibited Substance enters their bodies”, and “it is not necessary that intent, Fault, Negligence or knowing Use on the Athlete’s part be demonstrated”. The Code’s comment notes that the Court of Arbitration for Sport calls this “Strict Liability”.
A violation does not need a positive test. “The success or failure of the Use or Attempted Use of a Prohibited Substance … is not material.”
Possession of a substance prohibited out of competition is a violation unless the athlete shows it is consistent with a therapeutic use exemption “or other acceptable justification”.
For a Specified Substance, the default period of ineligibility is two years, before any reduction. It is four years where the anti-doping organisation “can establish that the anti-doping rule violation was intentional”.
The cases below show how admissions and reductions worked in practice.
03How has BPC-157 been handled in anti-doping since 2017?
A dated record of the List, the laboratories and the cases.
| Date | What happened |
|---|---|
| 2017 | The Sports Medicine Research and Testing Laboratory in Salt Lake City reports BPC-157 “identified in confiscated vials” and validates a urine method to detect it (Cox, Drug Testing and Analysis). |
| 14 Sep 2021 | WADA’s Executive Committee approves the 2022 List. |
| 30 Sep 2021 | WADA publishes it. For the first time, a substance is named as an example in S0: BPC-157, which WADA describes as “an experimental peptide sold as a supplement”. |
| 20 Oct 2021 | UK Anti-Doping tells athletes it “has now been listed as a prohibited substance”. |
| 1 Jan 2022 | The 2022 List takes effect. |
| 14 Sep 2023 | USADA announces a four-month sanction under the UFC anti-doping policy for an athlete who self-reported BPC-157 use. She had been prescribed it by a doctor; USADA said a therapeutic use exemption “was not applicable to this Non-Approved Substance”. |
| 30 Oct 2023 | The Shanghai Anti-Doping Laboratory publishes a urine method for BPC-157 and five metabolites (Tian, Molecules). |
| 3 Apr 2024 | Australia’s TGA cites the WADA listing among its reasons for scheduling BPC-157 as prescription-only. |
| 22 Aug 2024 | USADA reports a one-year sanction, imposed by an arbitrator, for a speed skater who never tested positive but declared using a supplement containing BPC-157. USADA notes the default for a specified substance “is two years”. |
| 17 Sep 2025 | USADA announces a four-year sanction for a triathlete who “possessed and used BPC-157 and TB-500” and used social media to encourage followers to purchase and use prohibited substances. TB-500 is a non-Specified Substance. |
| 13 May 2026 | Sport Integrity Australia warns athletes that peptides carry anti-doping risks and that they are accountable for any prohibited substance “no matter the source”. |
| 27 Jul 2026 | The Ghent doping control laboratory publishes a method covering 54 prohibited compounds, BPC-157 among them, in dried blood spots, serum and plasma (Mazzarino, Analyst). |
| 1 Jan 2027 | The 2027 List takes effect. |
The three US cases were built on a self-report, a declaration and a whistleblower-led investigation. None of them began with a positive test.
04How do national anti-doping bodies treat BPC-157?
The UK, Australia and the US all apply the same List. What differs is what each body has said about it.
| Country | Body | What it has said about BPC-157 |
|---|---|---|
| United Kingdom | UK Anti-Doping | Listed as prohibited from 2022. Athletes should be wary of supplements that market it, “as it is not approved for human consumption”. |
| Australia | Sport Integrity Australia | “A non-approved substance - prohibited at all times - and a specified substance”. A therapeutic use exemption “would not be granted for the use of BPC-157, in any medical condition”. |
| United States | USADA | “A specified substance in the category of Non-Approved Substances”, prohibited at all times; the three sanctions on this page were announced from 2023 to 2025. |
National medicines law does not move the sports listing. S0 turns on approval for human therapeutic use. Australia schedules BPC-157 as prescription-only (is BPC-157 legal in Australia?) and the UK has no authorisation for it (is BPC-157 legal in the UK?). The US HHS policy of October 2026 concerns compounding enforcement, not approval (is BPC-157 legal?).
05Can an athlete get a therapeutic use exemption for BPC-157?
The anti-doping bodies we read say no. Sport Integrity Australia: “A Therapeutic Use Exemption (TUE) would not be granted for the use of BPC-157, in any medical condition.” USADA, in the 2023 case where the athlete had a doctor’s prescription: a TUE “was not applicable to this Non-Approved Substance.” For peptides in general, Sport Integrity Australia adds that “A TUE is unlikely to be granted for an unregistered medicine”.
Detection methods exist. Anti-doping laboratories have published methods for BPC-157 in urine (2017 and 2023) and in dried blood spots, serum and plasma (2026). FDA staff note that the 2017 and 2023 studies worked from laboratory metabolism experiments and did not give BPC-157 to people.
06What changes in 2027?
WADA’s 2027 List keeps BPC-157 in S0 and adds “peptides” to the examples in the class definition. Its explanatory note says many peptides not approved for human use “fulfill the criteria of the World Anti-Doping Code for inclusion on the Prohibited List and fall under the S0 (Non-Approved Substances) class, or other classes (such as S2 or S4).” It adds: “Even if a peptide is not specifically named on the List, utmost caution should be taken as it may still be prohibited and may be harmful to health.”
For BPC-157 nothing changes: it was named before and is named still. The new wording matters for peptides that are not named. How the List treats other research peptides is on peptides and anti-doping.
07What we don’t know
How many cases there have been. WADA publishes testing figures; we have not analysed them for BPC-157. The cases on this page are three that USADA announced; we have not counted every BPC-157 case.
The basis of WADA’s 2021 re-evaluation. WADA’s notes say BPC-157 was added “following a recent re-evaluation” but do not set out the evidence.
The 2027 Code. We read the 2021 Code. WADA’s site links a 2027 edition of the Code, which we have not read.
The evidence on BPC-157 itself is in our BPC-157 research guide. Changes are logged in our regulatory changelog.
This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice, and athletes should check with their national anti-doping organisation.